Trial Type: Liver and Bile Duct Cancer

GPC3CD3 Trial
A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors
Status: Open
Trial Type: Colon Cancer, Esophageal Cancer, Liver and Bile Duct Cancer
Contact: Dr. Khaldoun Almhanna
kalmhanna@lifespan.org
PORT
GPC3/CD3 bispecific antibody for all solid tumors with GPC3 expression.
Status: Open
Trial Type: Early Phase Trials for Multiple Cancer Types, Liver and Bile Duct Cancer
Contact: Dr. Khaldoun Almhanna
kalmhanna@lifespan.org

©2024 Brown Cancer Clinical Trials